mRNA vaccines for infectious diseases: principles, delivery and clinical translation.
mRNA vaccines for infectious diseases: principles, delivery and clinical translation.
复制标题
DOI：
10.1038/s41573-021-00283-5
复制
发表时间：
2021-11
期刊：
影响因子：
--
通讯作者：
Whitehead KA
中科院分区：
文献类型：
--
作者：
Chaudhary N;Weissman D;Whitehead KA
在过去的几十年里，信使RNA（mRNA）疫苗已经从一个引起怀疑的想法发展到临床现实。2020年，COVID-19疫情催生了有史以来最快速的疫苗开发，mRNA疫苗处于这些努力的前沿。虽然现在已经清楚mRNA疫苗可以快速安全地保护患者免受感染性疾病的侵害，但还需要进一步的研究来优化mRNA设计，细胞内递送和SARS-CoV-2预防以外的应用。在这篇综述中，我们描述了mRNA疫苗的基础技术，重点是脂质纳米颗粒和其他非病毒载体。我们还概述了针对各种传染病病原体的mRNA疫苗的管道，并讨论了这一突破性疫苗平台未来应用的关键问题。2019冠状病毒病大流行确立了mRNA疫苗作为保护个人免受传染病侵害的快速、有效和安全方法。在这里，Whitehead及其同事回顾了mRNA疫苗设计、合成和递送的原理，评估了一系列传染病mRNA疫苗开发的最新进展和关键问题。
Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the most rapid vaccine development in history, with mRNA vaccines at the forefront of those efforts. Although it is now clear that mRNA vaccines can rapidly and safely protect patients from infectious disease, additional research is required to optimize mRNA design, intracellular delivery and applications beyond SARS-CoV-2 prophylaxis. In this Review, we describe the technologies that underlie mRNA vaccines, with an emphasis on lipid nanoparticles and other non-viral delivery vehicles. We also overview the pipeline of mRNA vaccines against various infectious disease pathogens and discuss key questions for the future application of this breakthrough vaccine platform. The COVID-19 pandemic has established mRNA vaccines as a rapid, effective and safe approach for the protection of individuals from infectious disease. Here, Whitehead and colleagues review the principles of mRNA vaccine design, synthesis and delivery, assessing recent progress and key issues in the development of mRNA vaccines for a range of infectious diseases.
登录
查看更多内容
影响因子：
--
作者：
Besin, Gilles;Milton, Jaclyn;Hoge, Stephen
通讯作者：
Hoge, Stephen
DOI：
10.1073/pnas.1306529110
发表时间：
2013-08-06
影响因子：
11.1
作者：
Alabi, Christopher A.;Love, Kevin T.;Anderson, Daniel G.
通讯作者：
Anderson, Daniel G.
影响因子：
12.4
作者：
Akinc, Akin;Goldberg, Michael;Anderson, Daniel G.
通讯作者：
Anderson, Daniel G.
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
DOI：
10.1038/mtna.2012.28
发表时间：
2012-08-14
期刊：
Molecular therapy. Nucleic acids
影响因子：
--
作者：
通讯作者：
--